Forum Topic News
  • Conversation: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

    • May 29, 2018 12:58 PM BST
    • Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

      Novartis announced today new real world evidence from the CHAMP-HF registry comparing Entresto® (sacubitril/valsartan) patients to patients not taking Entresto.[1] This pre-specified analysis of an interim data cut from the CHAMP-HF registry showed that chronic heart failure (HF) patients with reduced ejection fraction (HFrEF) taking Entresto reported early, statistically significant improvement in health status, as measured by the KCCQ-12 overall summary score (KCCQ-OS). [1] This finding was driven by statistically significant improvements in symptom frequency and quality of life domains of the KCCQ-12.[1] The study findings were presented today by lead investigator Yevgeniy Khariton, MD, MSc, Saint Luke's Hospital, Mid-America Heart Institute, University of Missouri-Kansas City, as a part of a late-breaking session at the European Society of Cardiology Heart Failure (ESC-HF) Congress in Vienna, Austria.
      Read more: http://www.worldpharmanews.com/novartis/4420-patient-reported-outcomes-tool-revealed-significant-improvement-in-symptom-frequency-and-quality-of-life-domains-with-entresto

Add Reputation

Do you want to add reputation for this member by this post?

or cancel